Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKinsey
Baxter
Moodys
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AIN457

See Plans and Pricing

« Back to Dashboard

Drug Development Status for AIN457: Patents, clinical trial progress, indications

AIN457 is an investigational drug.

There have been 47 clinical trials for AIN457. The most recent clinical trial was a Phase 3 trial, which was initiated on January 16th 2018.

The most common disease conditions in clinical trials are Psoriasis, Arthritis, and Arthritis, Psoriatic. The leading clinical trial sponsors are Novartis Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), and Novartis.

There are two US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for AIN457
TitleSponsorPhase
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)Novartis PharmaceuticalsPhase 3
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell ArteritisNovartis PharmaceuticalsPhase 2
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing SpondylitisNovartis PharmaceuticalsPhase 4

See all AIN457 clinical trials

Clinical Trial Summary for AIN457

Top disease conditions for AIN457
Top clinical trial sponsors for AIN457

See all AIN457 clinical trials

US Patents for AIN457

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AIN457   Start Trial Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)   Start Trial
AIN457   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Boehringer Ingelheim
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.